ASH Highlights

Idelalisib plus Bendamustine/Rituximab versus Bendamustine/Rituximab in Relapsed/Refractory CLL: Results of a Phase 3 Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Rituximab, Lenalidomide, and Ibrutinib as Frontline Therapy in Follicular Lymphoma: Results of the ALLIANCE 051103 Phase 1 Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Safety Overview of the CLLM1 Trial: Lenalidomide Maintenance Therapy After Frontline Chemoimmunotherapy in High-Risk CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Functional Evidence that Ibrutinib Blocks Leukemia Cell Proliferation and Trafficking and Promotes Leukemia Cell Death

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

The Combination of Alemtuzumab and Ofatumumab in Previously Untreated CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Ublituximab plus TGR-1202 in Heavily Pretreated and High-Risk CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Ibrutinib in Relapsed/Refractory CLL After Allogeneic Stem-Cell Transplant

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Dinaciclib plus Ofatumumab in Patients with Relapsed/Refractory CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Ibrutinib versus Ofatumumab in Patients with Relapsed/Refractory CLL in the RESONATE Study

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

The FCR2 Regimen: A Phase 2 Study of FCR-Lite and Lenalidomide in Frontline CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Page 10 of 15

5
6
7
8
9
10
11
12
13
14